SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has initiated studies of Adva-27a in xenograft mice. In these studies, specifically engineered mice which have developed tumors following injection with patient derived cancer cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors. Among the different types of patient derived cancer types being studied are Pancreatic Cancer, Breast Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.

Continue ReadingSUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER

Sunshine Biopharma Receives Vegan Certification for Essential 9 Amino Acids Supplement

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that it has received Vegan Certification for Essential 9TM from VegeCert.com in association with KASHRUTH COUNCIL…

Continue ReadingSunshine Biopharma Receives Vegan Certification for Essential 9 Amino Acids Supplement

Sunshine Biopharma Announces that Essential 9 is Now Available in the United States on Amazon.com

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that its recently launched micronutrients supplement, Essential 9TM, is now available in the United States on…

Continue ReadingSunshine Biopharma Announces that Essential 9 is Now Available in the United States on Amazon.com

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a ANTICANCER DRUG UNTIL 2033

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFMD”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of…

Continue ReadingSUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a ANTICANCER DRUG UNTIL 2033

SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms…

Continue ReadingSUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF Adva-27a ANTICANCER DRUG